1. An agent for the prevention or treatment of fatty liver disease containing ibudilast as an active ingredient. 2. The agent according to claim 1, wherein the fatty liver disease is a non-alcoholic fatty liver disease. The agent of claim 2, wherein the non-alcoholic fatty liver disease is non-alcoholic steatohepatitis. The agent according to claim 2, wherein the non-alcoholic fatty liver disease is simple fatty degeneration of the liver. The use of ibudilast for the prevention or treatment of fatty liver disease. 6. The use of claim 5, wherein the fatty liver disease is a non-alcoholic fatty liver disease. The use of claim 6, wherein the non-alcoholic fatty liver disease is non-alcoholic steatohepatitis. The use according to claim 6, wherein the non-alcoholic fatty liver disease is simple fatty liver dystrophy. The use of ibudilast as an active ingredient to obtain a means for the prevention or treatment of fatty liver disease. 10. The use of claim 9, wherein the fatty liver disease is a non-alcoholic fatty liver disease. The use of claim 10, wherein the non-alcoholic fatty liver disease is non-alcoholic steatohepatitis. The use of claim 10, wherein the non-alcoholic fatty liver disease is simple fatty liver disease. A method for the prevention or treatment of fatty liver disease, comprising administering an effective amount of an agent according to claim 1 for the prevention or treatment of fatty liver disease. The method of claim 13, wherein the fatty liver disease is a non-alcoholic fatty liver disease. The method of claim 14, wherein the non-alcoholic fatty liver disease is relatively small.1. Средство для профилактики или лечения жировой болезни печени, содержащее ибудиласт в качестве активного ингредиента.2. Средство по п.1, в котором жировой болезнью печени является неалкогольная жировая болезнь печени.3. Средство по п.2, в котором неалкогольной жировой болезнью печени является неалкогольный стеатогепатит.4. Средство по п.2, в котором неалкогольной жировой б
